RU2167664C2 - Anti-inflammatory and immunomodulating agent - Google Patents

Abstract

FIELD: medicine. SUBSTANCE: anti-inflammatory and immunomodulating agent has a homogenate fraction of cut-off placental villi dissolved in 0.95% sodium chloride solution. Invention can be used for treatment of patients with autoimmune diseases, chronic and acute inflammatory diseases associated with noncontrolled activation of respiratory "burst" of neutrophils. Proposed agent shows the purposeful effect providing inhibition of respiratory "burst". EFFECT: enhanced effectiveness of agent. 4 ex

Description

 The invention relates to medicine and can be used to treat autoimmune diseases, chronic and acute inflammatory diseases associated with uncontrolled activation of a respiratory “explosion” of neutrophils.

 A means of anti-inflammatory, immunomodulatory action (1) is known, containing denatured umbilical cord as an active principle, and distilled water as a diluent. A disadvantage of the known means is the multiple effect on the inflammatory process, the unsuitability of the means to achieve a targeted effect on the functions of the neutrophil.

 Closest to the claimed is an anti-inflammatory immunomodulatory agent (2), which contains, as an active principle, a part of the placental homogenate with amniotic membrane freed from coarse tissues. A disadvantage of the known means is that it does not suppress the respiratory "explosion" of neutrophils. However, in clinical practice, there is an increasing demand for targeted drugs that can change certain functions of cells - inflammation effectors. Broad-spectrum drugs have more side effects during therapy than targeted drugs.

 The problem to which the invention is directed, is to obtain an anti-inflammatory immunomodulatory means of targeted action, providing inhibition of the respiratory "explosion" of neutrophils.

 The task is achieved in that the product contains, as an active principle, a soluble fraction of the placental placenta homogenate soluble in a 0.95% sodium chloride solution.

Description of the invention
The anti-inflammatory immunomodulatory agent contains, as an active substance, a fraction of the villous placenta homogenate soluble in a 0.95% sodium chloride solution.

The tool is prepared as follows. As a raw material, the villous part of the human placenta is used, which is cut off after a preliminary examination, taking the unchanged part of the placenta (without signs of pathological changes: without necrosis, ischemia, signs of inflammation). After this, the placenta is washed in sterile saline and dried, for example, on filter paper. Then the placental tissue is homogenized (dispersed) until a homogeneous mass is obtained, for example, by grinding in a mortar in a small amount of physiological saline, which is subsequently adjusted to a final concentration of not less than 1:10 (1 part of homogenate: 10 parts of saline). The resulting suspension is centrifuged at room temperature for 15 minutes at 3000 rpm. The resulting supernatant (supernatant) is drained and used as an anti-inflammatory immunomodulatory agent. The product is stored in a freezer at a temperature of 20 ^o C and used as intended.

Proof of technical solution
To prove the technical effect, the obtained agent was tested in a model system using a standard HCT test, carried out in a 96-well immunological reaction plate, where a spontaneous HCT test was put in the first well, the induced HCT test with zymosan in the second, and the third induced HCT test with the addition of the claimed agent; in the fourth, the claimed agent was added to the patient’s blood sample, after which they were incubated at 3-7 ^° C for 10 minutes and a standard dose of zymosan was added. In this case, zymosan was used as an activator of the "respiratory explosion" of neutrophils to compare with the effect of the claimed drug.

Test Results
Example 1. Andreeva S.A. The diagnosis is severe gestosis. Indicators of the HCT test: spontaneous - 27%, induced with zymosan - 59%, induced HCT test with the addition of the claimed funds - 11%.

 Example 2. Pautenko A.A. The diagnosis is severe gestosis. Indicators of the HCT test: spontaneous - 26%, induced with zymosan - 45%, induced with the addition of the claimed funds - 17%.

 Example 3. Kononova M.N. The diagnosis is gestosis of moderate severity. Indicators of the HCT test: spontaneous - 30%, induced with zymosan - 61%, induced with the addition of the claimed funds - 16%.

 Example 4. Dronova L.G. The diagnosis is gestosis of moderate severity. Indicators of the HCT test: spontaneous - 23%, induced with zymosan - 58%, induced with the addition of the claimed agent - 9%, induced with the addition of the claimed agent + zymosan - 26%.

 As can be seen from the presented examples, the performance of the HCT test characterizing the oxygen-dependent microbicidal potential of neutrophils, after the introduction of the claimed funds are reduced by 2-2.5 times. From the last example it can be seen that the claimed agent blocks not only spontaneous, but also zymosan-induced activation of neutrophils. Thus, the tool allows you to inhibit the "respiratory explosion" of neutrophils.

List of sources used
1. RF patent N 2035910, A 61 K 35/50, Bull. N 15, 1995

 2. RF patent N 2063761, A 61 K 35/50, Bull. N 20, 1996

Claims (1)

 An anti-inflammatory, immunomodulating action agent containing placenta homogenate as an active principle, characterized in that it contains a soluble fraction of the homogenate of the villi cut off from the placenta in a 0.95% sodium chloride solution.